Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | SRC |
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | — |
| 06 May 2025 | Marco La Marca Cabinet member | Demographic Policy | — |
| 06 May 2025 | Marco La Marca Cabinet member | Demographic Policy | SRC |
| 10 Oct 2024 | Peter Van Kemseke Cabinet member | EB Summit | — |
| 10 Oct 2024 | Peter Van Kemseke Cabinet member | EB Summit | SRC |
| 12 Jun 2020 | Ursula von der Leyen President | Videoconference CEO of Amgen and CEO of Teneo (Topic: Preparation of Global Pledging Summit on 27 June) | SRC |
| 12 Jun 2020 | Ursula von der Leyen President | Videoconference CEO of Amgen and CEO of Teneo (Topic: Preparation of Global Pledging Summit on 27 June) | — |
| 17 May 2018 | Manuel Mateo-Goyet Cabinet member | Digital Health | — |
| 17 May 2018 | Manuel Mateo-Goyet Cabinet member | Digital Health | SRC |
Mission & Goals
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. Amgen has a presence in approximately 100 countries worldwide. It operates in one business segment : human therapeutics.
EU Legislative Interests
Engage governments and policy makers worldwide on issues important to Amgen to: Ensure patients have access to medicines they need. Provide coverage and reimbursement that reward innovation Introduce sound, science-based regulation. Enable biotechnology research and development (R&D)
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Amgen is a member or sponsor of the following organizations in Brussels: AmCham EU - American Chamber of Commerce to the EU EFPIA – European Federation of Pharmaceutical Industries and Associations Eucope - European Confederation of Pharmaceutical Entrepreneurs EPC - European Policy Centre European Business Summit ALDE
Organisation Members
N.A.
Connected Legislation